Recently, the atherogenic role of autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG), the principal protein component of high-density lipoprotein (HDL), has been investigated in clinical studies, showing that anti-apoA-1 IgG are associated with prevalent and incident CAD in subjects with autoimmune diseases, 5 subjects at high cardiovascular risk 6, 10 Objective-We aimed to determine whether autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG) predict incident coronary artery disease (CAD), defined as adjudicated incident myocardial infarction, angina, percutaneous coronary revascularization, or bypass grafting, in the general population. We further investigated whether this association is modulated by a functional CD14 receptor single nucleotide polymorphism. Approach and Results-In a prospectively studied, population-based cohort of 5220 subjects (mean age 52.6±10.7 years, 47.4% males), followed over a median period of 5.6 years, subjects positive versus negative for anti-apoA-1 IgG presented a total CAD rate of 3.9% versus 2.8% (P=0.077) and a nonfatal CAD rate of 3.6% versus 2.3% (P=0.018), respectively. After multivariate adjustment for established cardiovascular risk factors, the hazard ratios of anti-apoA-1 IgG for total and nonfatal CAD were: hazard ratio=1.36 (95% confidence interval, 0.94-1.97; P=0.105) and hazard ratio=1.53 (95% confidence interval, 1.03-2.26; P=0.034), respectively. In subjects with available genetic data for the C260T rs2569190 single nucleotide polymorphism in the CD14 receptor gene (n=4247), we observed a significant interaction between antiapoA-1 IgG and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the highest risk for total and nonfatal CAD in non-TT carriers, whereas being associated with the lowest risk for total and nonfatal CAD in TT homozygotes (P for interaction =0.011 and P for interaction =0.033, respectively). Conclusions-Anti-apoA-1 IgG are independent predictors of nonfatal incident CAD in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD. Visual Overview-An online visual overview is available for this article.
M
ajor discoveries in the pathophysiology of atherosclerosis have established the fundamental role of a chronic inflammatory state in the initiation, progression, and-finally-rupture of the atherosclerotic plaque. 1 During the last decade, humoral autoimmunity and autoantibodies have been recognized as important modulators of vascular inflammation and atherogenesis. 2 Autoantibodies can be active mediators in the development of coronary artery disease (CAD) 3, 4 and, as such, serve as biomarkers for the prediction of incident CAD [5] [6] [7] [8] [9] and as potential biological targets amenable to immunomodulatory therapies. associated with prevalent CAD, 11 as well as with all-cause mortality. 12 Nevertheless, their predictive value for incident CAD in the general population has not yet been studied.
From a pathophysiological point of view, in vitro and in vivo studies have demonstrated that anti-apoA-1 IgG per se behave as proinflammatory, proarrhythmogenic, and prothrombotic molecules, promoting atherogenesis, myocardial necrosis, and death in mice. 4, 13 Based on previous published studies, such events could be related to a chronic low-grade inflammatory state, 3, 14, 15 associations with elevated high-sensitivity C-reactive protein and increased uric acid levels, 11 impairment of HDL antiatherogenic properties, [16] [17] [18] interference with basal heart rate regulation, 7, 11, 15 or breakdown of self-tolerance. 12 However, the main pathophysiological mechanism-reported to date-underpinning the pathogenicity of anti-apoA-1 IgG is their interaction with innate immune system receptors and the activation of the TLR (Tolllike receptor)2/TLR4/CD14 complex. 14, 19 In particular, the current paradigm suggests that because of molecular mimicry of the C-terminal part of ApoA-1 to TLR2, anti-apoA-1 IgG bind to the TLR2/TLR4 complex and require a functional CD14 receptor for effective intracellular signaling, NF-κB (nuclear factor-κB) and MAPK (mitogen-activated protein kinase) downstream activation, and production of proinflammatory cytokines. 13 These findings point to CD14 receptor, the canonical ligand of lipopolysaccharide, as a major effector of the anti-apoA-1 IgG deleterious properties. A functional single nucleotide polymorphism at position C260T (rs2569190) of the CD14 receptor gene has been shown to modulate its transcriptional activity. 20, 21 Among the 3 groups of CD14 genotypes for rs2569190 (CC, CT, or TT), TT carriers seem to be protected from CD14 ligand-induced inflammation because of a better ability to adequately control the lipopolysaccharide-mediated TLR/CD14-dependent immune response. [22] [23] [24] Indeed, previous studies demonstrated that TT carriers were less at risk for gram-negative bacterial infection and sepsis death 25, 26 for developing heart failure, 27 as well as atherosclerosis, [28] [29] [30] although this latter observation is debated. 31 However, whether TT carriers are also less susceptible to anti-apoA-1 IgG-related atherosclerosis has not been examined. Thus, our current study had 2 main aims: first, we investigated whether anti-apoA-1 IgG predict incident CAD in the general population. Second, because of the anti-apoA-1 IgG role as a danger-associated molecular pattern, specifically activating CD14-related pathways, 4, 13 we further examined whether the functional C260T rs2569190 polymorphism in the CD14 receptor gene modulates the anti-apoA-1 IgGrelated CAD risk, hypothesizing a protective effect associated with carriage of the T allele.
Materials and Methods
Materials and Methods, including characterization analyses related to anti-apoA-1 IgG assay validation, are available in the online-only Data Supplement.
Results
Association Between Anti-apoA-1 IgG and Incident CAD Figure 1 demonstrates the flowchart of the study. Of the initial 6733 participants, 5220 had complete clinical and biological data over a median follow-up (FU) time of 5.6 years and were included in the final sample. Participants who did not participate in FU (21.6%) were more likely to be smokers, hypertensive, overweight with a less favorable lipid profile, compared with those included in the analysis. There were no significant differences in anti-apoA-1 IgG levels or prevalence of antiapoA-1 IgG positivity between the 2 groups ( Table I in the online-only Data Supplement). Table 2 ). On the contrary, no associations were observed between anti-apoA-1 IgG positivity or tertiles with fatal incident CAD. Sensitivity analyses after exclusion of subjects with baseline CAD or autoimmune disease yielded similar results for the associations between anti-apoA-1 IgG and total, nonfatal, and fatal CAD (Table II in the online-only Data Supplement). Additionally, statistical analyses after excluding adjustment for statin and β-blocker treatment or estimated glomerular filtration rate from the fully adjusted model yielded similar results (Table III in Interaction Between C260T rs2569190 Polymorphism and AntiapoA-1 IgG for Incident CAD Among genotyped subjects (n=4247; Figure 1 ), we further investigated whether the functional C260T rs2569190 polymorphism in the CD14 receptor gene modulates anti-apoA-1 IgG-related CAD risk. Subjects with missing genetic data tended to have a lower burden of cardiovascular risk factors and a higher prevalence of anti-apoA-1 IgG positivity (Tables IV and V in the online-only Data Supplement).
Characteristics of the genotyped sample according to the C260T rs2569190 polymorphism allele status are illustrated in Table VI in the online-only Data Supplement. All cardiovascular risk factors were equally distributed among subgroups, with the exception of an increased prevalence of diabetes mellitus and statin treatment in the TT subgroup. Importantly, the C260T rs2569190 polymorphism per se was not associated with total, nonfatal, or fatal incident CAD, all-cause mortality, or anti-apoA-1 IgG positivity (Table VI in the online-only Data Supplement). To assess differences in anti-apoA-1 IgG-related CAD risk according to the C260T rs2569190 polymorphism, we created both an additive (CC versus CT versus TT), as well as a recessive (CC/CT versus TT) model and performed a statistical test for the interaction 32 between anti-apoA-1 IgG and carriage of the T allele for total and nonfatal incident CAD risk. As previously, all analyses were adjusted for sex, age, smoking status, diabetes mellitus, systolic blood pressure, low-density lipoprotein and HDL cholesterol, baseline CAD, statin and β-blocker treatment, and estimated glomerular filtration rate.
In the case of the additive model (CC versus CT versus TT), we observed a gradient of risk for anti-apoA-1 IgG with regards to CAD across the 3 predefined C260T rs2569190 subgroups (Table 3) . Specifically, in the subgroup homozygote for the major allele (CC, n=1097), the adjusted anti-apoA-1 IgG HR for total CAD was HR, 2.27 (95% CI, (Table 3) .
Testing for the interaction between anti-apoA-1 IgG and C260T rs2569190 polymorphism with respect to CAD in the fully adjusted analysis indicated that the observed gradient in anti-apoA-1 IgG-related CAD risk across the different CD14 genotype subgroups in the additive (CC versus CT versus TT) model was statistically significant for both total and nonfatal CAD risk (P for interaction =0.011 and P for interaction =0.033, respectively; Table 3 ), proving substantial heterogeneity in anti-apoA-1 IgG-related CAD risk according to T allele carriage. A forest plot summarizes these findings ( Figure I in the online-only Data Supplement). Furthermore, statistical analyses after excluding adjustment for statin and β-blocker treatment or estimated glomerular filtration rate from the fully adjusted model yielded similar results (Table VII in the online-only Data Supplement). Figure 2 describes Kaplan-Meier curves for total and nonfatal CAD according to anti-apoA-1 IgG positivity and C260T rs2569190 allele status. Participants positive for antiapoA-1 IgG (Figure 2A and 2B) presented an increased risk for total and nonfatal CAD compared with those negative for anti-apoA-1 IgG. After splitting the positive anti-apoA-1 IgG group according to homozygous or not carriage of the T allele (CC/CT versus TT), a decrease in the proportion of total and nonfatal CAD was observed in the anti-apoA-1 IgG-positive TT subgroup ( Figure 2C and 2D, green line) , falling below the rate of CAD observed in anti-apoA-1 IgGnegative subjects ( Figure 2C and 2D, blue line). Conversely, higher proportion of total and nonfatal CAD was observed in anti-apoA-1 IgG-positive non-TT carriers ( Figure 2C and 2D, black line) when compared with anti-apoA-1 IgGpositive subjects as a whole ( Figure 2C and 2D, red line, log-rank: P=0.023 and P=0.017 for total and nonfatal CAD, respectively). Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs negative (OD<0.64) for anti-apoA-1 IgG. Statistical analysis by Cox proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes mellitus, smoking, HDL and LDL cholesterol, baseline CAD, statin, β-blocker treatment, and eGFR. Anti-apoA-1 IgG indicates anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; OD, optical density; and SD, standard deviation.
*Subjects with positive Anti-ApoA-1 (n=1040) were divided in tertiles (n=347) of increasing titers: first tertile (0.64<OD<0.77), second tertile (0.77<OD<0.98), and third tertile (OD>0.98).
Discussion
The main finding of the present study is that anti-apoA-1 IgG are independently associated with nonfatal incident CAD in the general population, with the anti-apoA-1 IgG-related CAD risk being strongly modulated by the C260T rs2569190 CD14 gene polymorphism. Indeed, after taking CD14 single nucleotide polymorphisms into account, we observed a significant anti-apoA-1 IgG-related CAD risk gradient, dependent on carriage of the C260T rs2569190 T allele, with non-TT carriers being at significantly increased risk for both total and nonfatal CAD compared with TT homozygotes. Our results extend current knowledge not only in the field of anti-apoA-1 IgG but also in the field of personalized CAD prediction in different ways.
First, similarly to what has been shown in high-risk populations, [5] [6] [7] 33 our current findings argue that anti-apoA-1 IgG positivity is an independent predictor of poor CV outcome in the general population, supporting the notion that preclinical autoimmunity to apoA-1 may identify a substantial proportion of individuals at increased risk of CAD. In our study, antiapoA-1 IgG-related CAD risk was highest in subjects carrying at least one C allele (CC/CT) in the functional C260T rs2569190 polymorphism, a group that represents roughly 3 quarters of White populations. 31 By virtue of being the first study on a gene-autoantibody interaction with respect to CAD, our analysis highlights the importance of incorporating genetic data on immune-related polymorphisms when evaluating anti-apoA-1 IgG-related risk and provides insight for future study design on individualized CAD prediction.
Second, these results represent a human validation of the key role of CD14 coreceptor in mediating the anti-apoA-1 IgG proatherogenic properties as demonstrated to date in animal and in vitro models 4, 13 and reinforce the relevance of these preclinical results to the anti-apoA-1 IgG-associated CAD risk in humans. Conversely, in line with a recent meta-analysis, 31 our findings are equivocal and do not provide definite evidence with regards to the association between TT genotype carriage and CAD risk.
Third, our data highlight the importance of considering the individual genetic information on innate immune receptors for proper assessment of CAD risk associated with biomarkers of humoral autoimmunity. To the best of our knowledge, none of the genetic studies published to date took into account biomarkers (including autoantibodies) for CAD risk prediction, and none of the publications exploring the auto-antibodies-associated CAD risk prediction evaluated the impact of individual genetic background on such risk. By demonstrating a potentially important gene-environment interaction between antiapoA-1 IgG and the CD14 receptor gene in the pathogenesis of atherosclerosis, our findings may explain the discordant findings regarding both the role of CD14 polymorphisms in CAD prediction 31 and the contrasting results of humoral auto-autoimmunity in CAD risk assessment. 33 Overall, our results provide a proof-of-concept that combining genetic data together with serum biomarkers is likely to be required for the implementation of precision medicine in the field of CAD prediction.
In our study, the fact that TT carriers were less at risk to develop anti-apoA-1 IgG-related CAD compared with Results are expressed as adjusted hazard ratios and (95% confidence interval) for subjects positive (OD>0.64) vs negative (OD<0.64) for anti-apoA-1 IgG. Statistical analysis by Cox proportional hazards regression adjusted for age, sex, systolic blood pressure, diabetes mellitus, smoking, HDL and LDL cholesterol, baseline CAD, statin, β-blocker treatment, and eGFR. The P value for interaction represents the likelihood of interaction between the C260T rs2569190 allele status and the relative anti-apoA-1 IgG effect for coronary artery disease. Anti-apoA-1 IgG indicates anti-apolipoprotein A-1 autoantibodies; CAD, coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low density lipoprotein; and OD, optical density.
non-TT carriers, despite TT homozygote status being previously associated with a higher systemic inflammatory profile, 20, 21 merits mention. To this respect, several lines of evidence indicate that TT genotype could confer protection against uncontrolled inflammatory response evoked by longterm danger-associated molecular pattern exposure through different and mutually nonexclusive mechanisms. First, previous studies indicate that in the context of chronic low-grade CD14/TLR4 stimulation, the higher levels of sCD14 ascribed to the TT genotype inhibit systemic lipopolysaccharide-mediated inflammatory responses by downregulating inflammatory cytokines transcription 34, 35 and facilitating CD14-related danger-associated molecular pattern clearance, 24 thus, protecting TT carriers against sustained inflammatory responses through a negative feedback mechanism. Inversely, lower levels of sCD14 observed in CC carriers have been shown to favor vascular wall inflammation and atherogenesis through impaired plasma clearance of endotoxin. 22, 23 C-allele carriers may be less able to prevent anti-apoA-1 IgG-mediated CD14/TLR4 activation, resulting in maintenance of a proatherogenic state and a higher risk for developing CAD. [28] [29] [30] Finally, increased expression of CD14 on the vascular endothelium of TT homozygotes 35 could also play a protective role in atherogenesis, in response to CD14 ligands such as anti-apoA-1 IgG. 22, 23, 34, 35 Several study limitations are noteworthy. First, although great effort was undertaken to maximize the participation rate during FU, our results may be subject to attrition bias as dropout rate after mean duration of 5.6 years was ≈20%. Nevertheless, similar losses in FU are commonly reported in prospective cohorts 36 and are within the conventional participation rate thresholds for cohort studies. 37 Second, we did not directly measure sCD14 in study subjects to confirm the presumed higher sCD14 levels in TT homozygote carriers reported previously. Moreover, as our assay assesses anti-apoA-1IgG antibodies against native apoA-1, 19,38 we were not able to measure antibodies against modified forms of apoA-1, such as oxidized apoA-1 (or possibly glycated and carbamylated apoA-1). Because these modified forms of apoA-1 were shown to be of relevance for HDL functionality and the pathology of atherosclerosis, [39] [40] [41] knowing whether they would elicit a humoral response clinically relevant to human physiopathology is still unclear. Third, because of sample availability, we only measured baseline anti-apoA-1 IgG levels and did not assess the dynamic of anti-apoA-1 IgG levels over time in relation with incident CAD. Moreover, we could not test other clinically relevant antibodies, such as anti-oxidized low-density lipoprotein, anti-phospholipid, antinuclear or antiheat shock protein antibodies, which would have been instrumental to better understanding potential associations with innate immune receptor-related genes of interest. Finally, sample size calculation in our study was performed with regards to the primary outcome of detecting a difference in incident CAD in subjects positive versus negative for anti-apoA-1 IgG. Although the fact that previous evidence suggested an interaction between anti-apoA-1 IgG and the CD14 receptor and that we were able to detect such a-significant-interaction between anti-apoA-1 IgG and the functional C260T rs2569190 polymorphism in the CD14 receptor gene, it is possible that the current sample size provided <80% power for this secondary study outcome. Therefore, this finding requires replication in larger prospective studies.
In conclusion, anti-apoA-1 IgG levels are independent predictors of incident nonfatal CAD in the general population. The strength of this association is significantly modulated by the functional C260T rs2569190 single nucleotide polymorphism in the CD14 receptor gene, being the highest in non-TT carriers and the lowest in TT homozygotes. These results imply that preclinical autoimmunity to apoA-1 should be evaluated carefully as it may help to improve the identification of individuals at increased risk of CAD in the general population, especially in non-TT carriers representing ≈75% of the population. Our findings indicate that geneautoantibodies interaction studies are likely to be required to better assess the CAD risk related to humoral autoimmunity biomarkers in the general population, a concept that requires further investigation.
